Shatavari (Asparagus racemosus)

Ayurvedic herbs — a standing contamination note

Heavy-metal contamination (lead, mercury, arsenic) has been documented across a meaningful share of commercially sold Ayurvedic herbal products, as a product-manufacturing/sourcing risk layered on top of — not a substitute for — each herb's own safety profile above. One peer-reviewed cluster investigation found lead in 65% of 252 tested samples, mercury in 38%, and arsenic in 32%, with concentrations in many samples exceeding safe daily intake by up to several thousand times. An earlier study found 1 in 5 sampled products exceeded safety thresholds for at least one heavy metal. The FDA has separately issued a warning about heavy-metal poisoning linked to unapproved Ayurvedic drug products. Researchers attribute this mainly to raw-material sourcing rather than universal intentional adulteration — it is not eliminated just by choosing a well-known brand. Applies to every item in this group: ashwagandha, shatavari, tribulus terrestris (gokshura), safed musli, and shilajit.

The verdict

An animal pregnancy-exposure study found estrogenic tissue changes on the exact gestation window a trying-to-conceive user could unknowingly be in; its main real-world use (as a lactation aid) rests on weak or manufacturer-funded human evidence, not independent proof it works.

An Ayurvedic root, traditionally used as a women's reproductive tonic and, especially, as a postpartum lactation aid — the latter is its dominant real-world use case in India.

What the evidence shows

Fertility/menopause evidence: recent trials exist for sexual wellness and menopausal symptoms (RCTs, 100+ participants); a 2025 fertility-specific review calls the herb "promising" but says fertility-specific trials remain limited, especially for male fertility where evidence is essentially absent.

Lactation evidence (its main marketed use): one human trial measured only a prolactin surrogate, not milk output; the one trial that measured actual milk volume and found a difference was funded by, and co-authored with a director of, the company that makes the branded product tested (ACT Lifesciences / Shavari Bar®) — a direct conflict of interest. A 2013 systematic review found the overall evidence for herbal galactogogues, shatavari included, inadequate to guide clinical recommendations.

Evidence tier

Documented harm

⛔ Peer-reviewed evidence of serious adverse effects from the item's own chemistry/pharmacology or a well-characterized allergic mechanism. More serious than contamination; not resolved by buying a 'reputable brand'.

Sources

Take this further

Last reviewed 14 July 2026.